OncLive TV

Jubilee Brown, MD, discusses the clinical implications of the phase 3 PRIMA trial in advanced ovarian cancer.

Elise Nassif, MD, discusses the efficacy of early-phase clinical trials in soft tissue sarcoma.

Mothaffar Fahed Rimawi, MD, discusses mitigating interstitial lung disease/pneumonitis in HER2-positive breast cancer.

Erika P. Hamilton, MD, discusses the potential integration of novel selective estrogen receptor degraders into the treatment armamentarium for ER-positive, HER2-negative breast cancer.

Julie M. Vose, MD, MBA, discusses the use of CAR T-cell therapy in non-Hodgkin lymphoma.

Ritu Salani, MD, MBA, discusses the rationale for combinations of immunotherapy and PARP inhibitors in ovarian cancer.

Denise A. Yardley, MD, discusses the efficacy achieved with ribociclib plus letrozole in patients with hormone receptor–positive, HER2-negative advanced breast cancer.

Anish Thomas, MD, discusses potential biomarkers of response to the combination of berzosertib plus topotecan in patients with relapsed, platinum-resistant small cell lung cancer.

Sanjay Popat, BSc, MBBS, FRCP, PhD, discusses the clinical implications of the final results of the phase 3 ALTA-1L trial in ALK-positive non–small cell lung cancer. Scroll to 0:07 in the video for Dr. Popat's topline points on the data.

Alexander I. Spira, MD, PhD, FACP, discusses the role of frontline brigatinib in ALK-positive non–small cell lung cancer.

Bijal Shah, MD, MS, discusses the FDA approval of brexucabtagne autoleucel in relapsed/refractory B-cell acute lymphoblastic leukemia.

Angeles A. Secord, MD, discusses treating patients with platinum-sensitive ovarian cancer.

Brandon Blue, MD, discusses the utility of carfilzomib in relapsed/refractory multiple myeloma.

Kim Chi, MD, discusses future research directions with PARP inhibitors in metastatic prostate cancer.

Daniela Sia, PhD, discusses a novel microenvironment-based classification system of intrahepatic cholangiocarcinoma.

Nasser Khaled Altorki, MD, discusses the results of post-hoc analyses of the phase 3 IMpower010 trial in non–small cell lung cancer.

Omid Hamid, MD, discusses the integration of tumor infiltrating lymphocyte–based therapy into the melanoma armamentarium.

Bhagirathbhai Dholaria, MBBS, discusses the rationale for the phase 1 MagnetisMM-1 trial in relapsed/refractory multiple myeloma.

Rohit Jain, MD, MPH, discusses the data from the phase 3 JAVELIN Bladder 100 trial examining avelumab as maintenance therapy following response or stable disease with first-line platinum-based chemotherapy in patients with advanced or metastatic urothelial cancer.

Sara A. Hurvitz, MD, discusses the rationale for the phase 2 coopERA Breast Cancer trial in estrogen receptor–positive, HER2-negative breast cancer.

Jared Weiss, MD, discusses the efficacy results of the ongoing phase 1/2 KRYSTAL-1 trial in KRAS G12C–mutated colorectal cancer.

Douglas W. Sborov, MD, MS, discusses management strategies for bispecific antibody–related adverse effects in multiple myeloma.

Rachid Baz, MD, discusses the utility of venetoclax in patients with heavily pretreated multiple myeloma.

Maryam Lustberg, MD, MPH, discusses ongoing research in breast cancer.

Floor J. Backes, MD, discusses challenges regarding staging and treatment locations in ovarian germ cell tumors.

Andrea L. Silber, MD, discusses the importance of improving clinical trial inclusivity in breast cancer.

Alexander M. Lesokhin, MD, discusses the utility of elranatamab in the ongoing phase 2 MagnetisimMM-3 trial in relapsed/refractory multiple myeloma.

Kim Chi, MD, discusses the design of the phase 3 AMPLITUDE trial in metastatic castration-sensitive prostate cancer.

Elisabet E. Manasanch, MD, discusses eligibility for autologous stem cell transplant in patients with multiple myeloma.

Martine Extermann, MD, PhD, discusses the significance of novel treatment options in HER2-positive breast cancer.